← Back to Search

Anti-tumor antibiotic

Doxil + Hyperthermia for Breast Cancer

Phase 2

Waitlist Available

Led By Leonard R. Prosnitz, M.D.

Research Sponsored by National Center for Research Resources (NCRR)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with recurrent or metastatic breast cance

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is for patients with recurrent breast cancer located on the chestwall or metastatic breast cancer.

Who is the study for?

This trial is for breast cancer patients who have recurrent cancer on the chest wall after mastectomy or those with stage IV disease and advanced tumors in the breast. It's not suitable for people without these specific conditions.Check my eligibility

What is being tested?

The study tests a combination of Doxil, a form of chemotherapy, with heat treatment to see if it can better target tumor tissue and enhance response while reducing overall toxicity. Patients will undergo this combined therapy every 4 weeks for six cycles.See study design

What are the potential side effects?

Doxil may cause side effects such as fatigue, nausea, hair loss, mouth sores, and low blood cell counts leading to increased infection risk. Heat treatment could potentially add discomfort or skin burns at the site of application.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Center for Research Resources (NCRR)Lead Sponsor

537 Previous Clinical Trials

317,016 Total Patients Enrolled

5 Trials studying Breast Cancer

1,001 Patients Enrolled for Breast Cancer

Leonard R. Prosnitz, M.D.Principal Investigator

Media Library

Doxil (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT00006433 — Phase 2

Breast Cancer Clinical Trial 2023: Doxil Highlights & Side Effects. Trial Name: NCT00006433 — Phase 2

Doxil (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006433 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the window of opportunity to join this clinical research still available?

"According to data hosted on clinicaltrials.gov, this trial is not presently seeking participants. It was initially presented in January 2000 and last revised June 2005; however, there are currently 2596 other trials that have open recruitment slots."

Answered by AI

Is this treatment a viable option with minimal risks to patients?

"Although no evidence is available to support the efficacy of this treatment, it can be considered relatively safe and was thus given a rating of 2."

Answered by AI

Are there any age restrictions for entry into this trial?

"In accordance with the requirements for this clinical trial, minors are not eligible to participate as the minimum age is 18; however, seniors can take part in the study up until they reach 90 years of age."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer

2000. "Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006433.

All > North Carolina > Breast